Krystal Biotech Dirección
Dirección controles de criterios 4/4
El CEO de Krystal Biotech es Krish Krishnan , nombrado en Dec 2015, tiene una permanencia de 8.92 años. compensación anual total es $6.22M, compuesta por 11.8% salario y 88.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 5.43% de las acciones de la empresa, por valor de $278.24M. La antigüedad media del equipo directivo y de la junta directiva es de 2.8 años y 6.4 años, respectivamente.
Información clave
Krish Krishnan
Chief Executive Officer (CEO)
US$6.2m
Compensación total
| Porcentaje del salario del CEO | 11.8% |
| Permanencia del CEO | 8.9yrs |
| Participación del CEO | 5.4% |
| Permanencia media de la dirección | 2.8yrs |
| Promedio de permanencia en la Junta Directiva | 6.4yrs |
Actualizaciones recientes de la dirección
Recent updates
Krystal Biotech, Inc. (NASDAQ:KRYS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
Nov 07
Krystal Biotech: Q4 Catalysts Expected With VYJUVEK Revenue Growth Pressing On
Oct 14Krystal Biotech: High Valuation Merits Caution Ahead Of Q2 Earnings (Rating Downgrade)
Jul 31Krystal Biotech's (NASDAQ:KRYS) Earnings Might Be Weaker Than You Think
May 13Krystal Biotech's Future Brightens With Vyjuvek's Robust Launch
Feb 28Krystal Biotech: Ready For Launch
Feb 20We Think Krystal Biotech (NASDAQ:KRYS) Can Easily Afford To Drive Business Growth
Jan 02Companies Like Krystal Biotech (NASDAQ:KRYS) Can Afford To Invest In Growth
Sep 06Are Investors Undervaluing Krystal Biotech, Inc. (NASDAQ:KRYS) By 46%?
Aug 08We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth
May 17We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely
Jan 30Krystal Biotech cleared to file EU marketing application for rare skin disease therapy
Sep 22We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth
Aug 30Krystal Biotech: Solid Performance, Let's Keep Holding
Aug 18Krystal Biotech GAAP EPS of -$1.10 misses by $0.07
Aug 08Krystal gets FDA nod to start trial of gene therapy KB407 for cystic fibrosis
Aug 01Krystal Biotech: High Potential, Buy-At-Dips Stock
May 25We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely
Apr 20Krystal Biotech: The Future Looks More And More Derisked
Feb 21Krystal Biotech Establishes Proof Of Concept With STAR-D Platform; Opens Door For More Skin Indications
Nov 30Krystal Biotech: A Buy Ahead Of Their Pivotal DEB P3 Trial Readout
Sep 27Here's Why We're Not Too Worried About Krystal Biotech's (NASDAQ:KRYS) Cash Burn Situation
Sep 25Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$52m |
| Jun 30 2024 | n/a | n/a | US$106m |
| Mar 31 2024 | n/a | n/a | US$57m |
| Dec 31 2023 | US$6m | US$733k | US$11m |
| Sep 30 2023 | n/a | n/a | -US$30m |
| Jun 30 2023 | n/a | n/a | -US$140m |
| Mar 31 2023 | n/a | n/a | -US$135m |
| Dec 31 2022 | US$3m | US$645k | -US$140m |
| Sep 30 2022 | n/a | n/a | -US$130m |
| Jun 30 2022 | n/a | n/a | -US$115m |
| Mar 31 2022 | n/a | n/a | -US$104m |
| Dec 31 2021 | US$7m | US$581k | -US$70m |
| Sep 30 2021 | n/a | n/a | -US$58m |
| Jun 30 2021 | n/a | n/a | -US$52m |
| Mar 31 2021 | n/a | n/a | -US$43m |
| Dec 31 2020 | US$764k | US$498k | -US$32m |
| Sep 30 2020 | n/a | n/a | -US$27m |
| Jun 30 2020 | n/a | n/a | -US$22m |
| Mar 31 2020 | n/a | n/a | -US$20m |
| Dec 31 2019 | US$631k | US$366k | -US$19m |
| Sep 30 2019 | n/a | n/a | -US$17m |
| Jun 30 2019 | n/a | n/a | -US$16m |
| Mar 31 2019 | n/a | n/a | -US$13m |
| Dec 31 2018 | US$705k | US$200k | -US$11m |
| Sep 30 2018 | n/a | n/a | -US$9m |
| Jun 30 2018 | n/a | n/a | -US$11m |
| Mar 31 2018 | n/a | n/a | -US$10m |
| Dec 31 2017 | US$69k | US$69k | -US$8m |
Compensación vs. Mercado: La compensación total ($USD6.22M) de Krish está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD7.94M).
Compensación vs. Ingresos: La compensación de Krish ha sido consistente con los resultados de la empresa en el último año.
CEO
Krish Krishnan (59 yo)
8.9yrs
Permanencia
US$6,223,894
Compensación
Mr. Krish S. Krishnan, M.S., M.B.A., is Founder of Krystal Biotech, Inc. since December 2015. He has been President, Chief Executive Officer and Chairman at Krystal Biotech, Inc. since December 2015. Mr. K...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 8.9yrs | US$6.22m | 5.43% $ 278.2m | |
| Founder | 8.9yrs | US$3.84m | 5.53% $ 283.3m | |
| Executive VP & Chief Accounting Officer | 4.8yrs | US$2.57m | 0.045% $ 2.3m | |
| General Counsel & Corporate Secretary | no data | sin datos | sin datos | |
| Vice President of North American Sales & Marketing | no data | sin datos | sin datos | |
| Head of U.S. Sales & Marketing | less than a year | sin datos | sin datos | |
| Vice President of Corporate Development | no data | sin datos | sin datos | |
| Director of Human Resources & Operations | no data | sin datos | sin datos | |
| Senior VP & GM of Europe | no data | sin datos | sin datos | |
| Senior Vice President of Clinical Development | 2.8yrs | sin datos | sin datos | |
| Senior Vice President of Patient Access | less than a year | sin datos | sin datos | |
| Senior Vice President of Global Value and Access | less than a year | sin datos | sin datos |
2.8yrs
Permanencia media
59yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de KRYS se considera experimentado (2.8 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 8.9yrs | US$6.22m | 5.43% $ 278.2m | |
| Founder | 8.8yrs | US$3.84m | 5.53% $ 283.3m | |
| Lead Independent Director | 8yrs | US$610.32k | 0.37% $ 19.1m | |
| Independent Director | 7.4yrs | US$584.82k | 0.27% $ 14.0m | |
| Independent Director | 5.7yrs | US$585.07k | sin datos | |
| Independent Director | 2.8yrs | US$570.44k | 0% $ 0 | |
| Independent Director | 3.8yrs | US$568.32k | 0% $ 0 | |
| Non-Employee Independent Director | 7.2yrs | sin datos | sin datos | |
| Independent Director | 1.7yrs | US$934.43k | 0% $ 0 | |
| Chairman of Scientific Advisory Board | 4.8yrs | sin datos | sin datos |
6.4yrs
Permanencia media
59yo
Promedio de edad
Junta con experiencia: La junta directiva de KRYS se considera experimentada (6.4 años de antigüedad promedio).